Clinical Trials & Research
Oncology Nurse Navigators
High-Risk Cancer Genetics
See All Your Doctors in One Visit
Events & Support Groups
Fitness & Wellness
Home > Testing & Treatment > Surgery > MarginProbe® for Breast Lumpectomy
Hall-Perrine Cancer Center at Mercy Medical Center is the first and only hospital in Iowa using MarginProbe® technology during early-stage breast lumpectomy surgeries. It allows surgeons to understand whether cancer is present in the tissue during surgery as opposed to waiting several days after surgery for the pathology report. MarginProbe reduces re-excision rates (the need for a second surgery) by 61%.
Having a “clean margin” around the site of the cancer is important to increase the likelihood of a successful outcome through that course of treatment. Therefore, all cancer cells must be fully eliminated at the edge of the removed tissue.
During surgery, the surgeon uses a probe to test the margins of removed tissue. Within minutes, the MarginProbe System provides real-time, detailed information indicating whether cancer remains at the edge of the removed tissue. This aids the surgeon in deciding whether to remove additional tissue or to complete the lumpectomy procedure and close the incision.
MarginProbe detects cancer by assessing the electromagnetic response of tissue. The system allows the surgeon to probe suspect tissue, capturing microscopic differences in electromagnetic properties. The system characterizes the tissue’s electromagnetic signature and then compares those responses to an internal database of known signatures in healthy and cancerous tissues.
Read an article from Dilon Technologies, Inc. highlighting Dr. Reid’s findings using MarginProbe®: "Physician Insight for Patients: Dr. Vincent Reid – MarginProbe® Shrinks Positive Margin Rates and Tissue Volume Removed for Both Invasive and DCIS Breast Cancers."
Vincent Reid, MD, FACS,Oncologic Surgeon
Watch a video on "Common Misconceptions About Mastectomy vs Lumpectomy."
Visit the MarginProbe® website.